CTC
AUPH icon

Central Trust Company’s Aurinia Pharmaceuticals AUPH Stock Holding History

Central Trust Company’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.6K Buy
+1,688
New +$27K ﹤0.01% 1000
2021
Q2 		– Sell
-370
Closed -$5K – 1184
2021
Q1 		$5K Buy
+370
New +$5.37K ﹤0.01% 999

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Central Trust Company's AUPH Position: Q2 2026 in Review

Central Trust Company opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 1,688 shares worth $28.6K. The stake represents ﹤0.01% of the portfolio and ranks #1000 among its holdings. This is a return to the name: Central Trust Company previously reported a position in AUPH as recently as Q1 2021.

Central Trust Company first reported a position in AUPH in Q1 2021 and has held it in 2 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Central Trust Company held 1,688 shares of Aurinia Pharmaceuticals worth $28.6K as of Q2 2026.
  • Aurinia Pharmaceuticals was a new Central Trust Company position in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1000 holding.
  • Central Trust Company first reported a position in Aurinia Pharmaceuticals in Q1 2021 and has held it in 2 quarters since.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.